National shared care protocol:

Dexamfetamine for patients within adult services

1 January 2025, Version 1

TLS Amber – 3 months

Review date – January 2028

The content of this shared care protocol was correct as of January 2022. As well as these protocols, please ensure that summaries of product characteristics (SPCs), British national formulary (BNF) or the Medicines and Healthcare products Regulatory Agency (MHRA) or NICE websites are reviewed for up-to-date information on any medicine.

Specialist responsibilities

- Assess the patient and provide diagnosis. Ensure the diagnosis is within scope of this shared care protocol (section 2) and communicated to primary care.
- Use a shared decision making approach; discuss the benefits and risks of the treatment with the patient and/or their carer and provide the appropriate counselling (see section 11), to enable the patient to reach an informed decision. Obtain and document patient consent. Provide an appropriate patient information leaflet.
- Ensure the patient and/or their carer understands that treatment may be stopped if they do not attend for monitoring and treatment review
- Assess for contraindications and cautions (see section 4) and interactions (see section 7).
- Conduct required baseline investigations and initial monitoring (see section 8).
- Initiate and optimise treatment as outlined in section 5. Prescribing is normally for at least 12 weeks until the patient is stable and dose optimised.
- Prescribe in line with controlled drug prescription requirements (section 6).
- Once treatment is optimised, complete the shared care documentation and send to patient's GP practice detailing the diagnosis, current and ongoing dose, any relevant test results and when the next monitoring is required. Include contact information (section 13).
- Prescribe sufficient medication to enable transfer to primary care, including where there are unforeseen delays to transfer of care.
- Conduct the required monitoring in section 8 and communicate the results to primary care. This monitoring, and other responsibilities below, may be carried out by a healthcare professional in primary or secondary care with expertise and training in ADHD, depending on local arrangements.
- Determine the duration of treatment and frequency of review. After each review, advise primary care whether treatment should be continued, confirm the ongoing dose, and whether the ongoing monitoring outlined in section 9 remains appropriate. Trial discontinuations can be managed in primary care within the competence of the prescriber (section 8) with advice/input from the specialist.
- Prescribing when a woman becomes or wishes to become pregnant can be managed in primary care with advice/input from the specialist.
- Provide advice to primary care on the management of adverse effects if required.

Primary care responsibilities

- Respond to the request from the specialist as soon as practicable if they are **unable** to support shared care (in writing or via secure email). It is asked that this be undertaken within 14 days of the request being made, where possible.

- If shared care is accepted, prescribe ongoing treatment as detailed in the specialists request and as per section 5 taking into account any potential drug interactions in section 7.
- Prescribe in line with controlled drug prescription requirements (section 6).
- Adjust the dose of dexamfetamine prescribed as advised by the specialist.
- Conduct the required monitoring as outlined in section 9. Communicate any abnormal results to the specialist.
- Assess for possible interactions with dexamfetamine when starting new medicines (see section 7)
- Manage adverse effects as detailed in section 10 and discuss with specialist team when required.
- Stop dexamfetamine and make an urgent referral for appropriate care when contra-indications are suspected.
- Seek advice/input from the specialist if the patient becomes or plans to become pregnant.
- Stop treatment as advised by the specialist. Trial discontinuations can be managed in primary care within the competence of the prescriber with advice/input from the specialist.

Patient and/or carer responsibilities

- Take dexamfetamine as prescribed and avoid abrupt withdrawal unless advised by their prescriber.
- Attend regularly for monitoring and review appointments with primary care and specialist, and keep contact details up to date with both prescribers. Be aware that medicines may be stopped if they do not attend.
- Report adverse effects to their primary care prescriber. Seek immediate medical attention if they develop any symptoms as detailed in section 11.
- Report the use of any over the counter (OTC) medications to their prescriber and be aware they should discuss the use of dexamfetamine with their pharmacist before purchasing any OTC medicines.
- Be aware that dexamfetamine can affect cognitive function and is subject to drug driving laws, therefore patients must ensure their ability to drive is not impaired before driving (see section 11).
- Avoid alcohol while during treatment, as it may make some side effects worse. Avoid recreational drugs.
- Dexamfetamine is a schedule 2 controlled drug. Patients may be required to prove their identity when collecting prescriptions and should store dexamfetamine safely and securely. It must not be shared with anyone else.

- Patients of childbearing potential should take a pregnancy test if they think they could be pregnant and inform the specialist or GP immediately if they become pregnant or wish to become pregnant.

1. Background

Back to top

Dexamfetamine sulfate is a sympathomimetic amine with central stimulant and anorectic activity indicated for the treatment of attention deficit hyperactivity disorder (ADHD). It may be offered as an alternative treatment in patients who have been appropriately diagnosed and whose symptoms are responding to lisdexamfetamine but are unable to tolerate the drug's longer effect profile (see NICE Guidance NG87 Attention deficit hyperactivity disorder: diagnosis and management). NICE recommends that people with ADHD have a comprehensive, holistic shared treatment plan that addresses psychological, behavioural and occupational or educational needs.

Dexamfetamine is not licensed for all the indications listed in section 2. However, its use for the indications below are established and supported by various sources and bodies including the BNF and NICE.

Dexamfetamine is a schedule 2 controlled substance; all legal requirements for prescribing controlled drugs should be followed. See NICE Guidance NG46 Controlled drugs: safe use and management.

Where a person with ADHD is treated by a Child and Adolescent Mental Health Service (CAMHS) but is approaching their 18th birthday, it is expected that CAMHS will refer to the appropriate adult service if need for ongoing treatment is anticipated.

Long-term usefulness of dexamfetamine for extended periods (over 12 months) should be periodically re-evaluated by a healthcare professional with expertise in ADHD for the individual patient with trial periods off medication to assess the patient's functioning without pharmacotherapy. It is recommended a trial discontinuation at least once yearly to assess the patient's condition. Improvement may be sustained when the medicinal product is either temporarily or permanently discontinued.

2. Indications

Back to top

- Attention deficit hyperactivity disorder (ADHD) in adults ‡

‡ Off-label indication. (Please note licensed indications vary by manufacturer. See SPCs for full details).

3. Locally agreed off-label use

Back to top

To be agreed and completed locally (include supporting information)

N/A

4. Contraindications and cautions

Back to top

This information does not replace the Summary of Product Characteristics (SPC), and should be read in conjunction with it. Please see BNF & SPC for comprehensive information.

Contraindications:

- Known hypersensitivity to the active substance, any of the excipients, or sympathomimetic amines. Note: some dexamfetamine brands may contain isomalt which is unsuitable for people with fructose intolerance.
- Glaucoma
- Phaeochromocytoma or porphyria
- Concomitant use of monoamine oxidase inhibitors (MAOI) or within 14 days of MAOI treatment
- Hyperthyroidism or thyrotoxicosis.

For patients with the following contraindications, dexamfetamine can be prescribed under certain circumstances after a risk benefit consideration by the specialist has been taken into account:

- Certain pre-existing cardiovascular disorders constitute contraindications unless specialist cardiac advice is obtained and documented. These include; structural cardiac abnormalities and/or moderate hypertension, heart failure, arterial occlusive disease, angina, haemodynamically significant congenital heart disease, cardiomyopathies, myocardial infarction, potentially life-threatening arrhythmias and channelopathies (disorders caused by the dysfunction of ion channels)
- Severe depression, anorexia nervosa/anorexic disorders, suicidal ideation, hyperexcitability, psychotic symptoms, severe and episodic (Type I) Bipolar (affective) Disorder (that is not well-controlled), schizophrenia, psychopathic/borderline personality disorder
- Cerebrovascular disorders (cerebral aneurysm, vascular abnormalities including vasculitis or stroke)
- Gilles de la Tourette syndrome or similar dystonias
- History of drug abuse or alcohol abuse

Cautions:

- History of epilepsy (discontinue if seizures occur)
- Mild hypertension, history of cardiovascular disease, or concomitant medications that elevate blood pressure
- susceptibility to angle-closure glaucoma
- Psychiatric and neuropsychiatric symptoms or disorders, including manic or psychotic symptoms, aggressive or hostile behaviour, tics, anxiety/agitation, or bipolar disorder
- Depressive symptoms; patients should be screened for risk of bipolar disorder, including psychiatric and family histories.
- Renal and hepatic insufficiency (due to lack of data).
- Family history of sudden cardiac or unexplained death or malignant arrhythmia
- Pregnancy or breast-feeding (see section 12)
- Potential for abuse, misuse, or diversion.

5. Initiation and ongoing dose regimen

Back to top

- Transfer of monitoring and prescribing to primary care is normally after the patient has been on treatment for at least 12 weeks, is stable and the dose optimised with satisfactory investigation results for at least 4 weeks.
- The duration of treatment & frequency of review will be determined by the specialist, based on clinical response and tolerability.
- Dose or formulation adjustments can be managed in primary care with advice/input from the specialist.
- Termination of treatment can be managed in primary care within the competence of the prescriber (section 8) with advice/input from the specialist.

Initial stabilisation:

ADHD: Initially 5 mg twice daily, dose should be increased according to response at intervals no shorter than 1 week.

Dexamfetamine must be prescribed by the initiating specialist during initiation and dose stabilisation.

Maintenance dose (following initial stabilisation):

ADHD: maximum 60 mg per day to be given in 2–4 divided doses;

The initial maintenance dose must be prescribed by the initiating specialist.

Conditions requiring dose adjustment:

Consider trial periods of stopping medication or reducing the dose when assessment of the overall balance of benefits and harms suggests this may be appropriate. This should be undertaken and supervised by the specialist who will advise the patient and primary care prescriber of the outcome. Alternatively, this can be managed in primary care within the competence of the prescriber (section 8).

6. Pharmaceutical aspects

Back to top

Route of administration:	Oral
Formulation:	Dexamfetamine sulfate 5mg, 10mg and 20mg immediate release tablets (Amfexa®) Dexamfetamine sulfate 5mg immediate release tablets Dexamfetamine sulfate 5mg/5mL sugar-free oral solution▼ Please note licensed indications vary by manufacturer. See SPCs for full details
Administration details:	Tablets can be halved Dexamfetamine should not be taken too late after lunch time to avoid disturbances of sleep • If a dose is missed then the next scheduled dose should be taken as usual; a double dose should not be taken to make up for a missed dose.
Other important information:	Dexamfetamine is a schedule 2 controlled drug and is subject to legal prescription requirements. It has the potential for misuse and diversion. Patients should be advised to avoid alcohol which may exacerbate the central nervous system (CNS) side-effects of dexamfetamine. Dexamfetamine is subject to additional monitoring by the Medicines and Healthcare products Regulatory Agency (MHRA) and healthcare professionals are encouraged to report any suspected adverse reactions Amfetamines can cause a significant elevation in plasma corticosteroid levels. This increase is greatest in the evening. Amfetamines may interfere with urinary steroid determinations

	In times of medicine shortages, local guidance is available to support clinicians to manage supply disruptions. Management of Stock Shortages (Remedy BNSSG ICB)

7. Significant medicine interactions

Back to top

The following list is not exhaustive. Please see BNF or SPC for comprehensive information and recommended management.

The following medicines must not be prescribed without consultation with the specialist:

- **Mono-amine oxidase inhibitors (MAOIs) and other sympathomimetics** (e.g. rasagiline, selegiline, safinamide) – additive hypertensive effect
- **Clonidine** – increased duration of action of dexamfetamine, reduced antihypertensive action of clonidine

Other clinically significant interactions

- **Coumarin anticoagulants, anticonvulsants, selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs)**: metabolism may be inhibited by dexamfetamine. Dose adjustment may be required when starting or stopping dexamfetamine.
- **SSRIs (e.g. fluoxetine, paroxetine)**: may increase exposure to dexamfetamine. Risk of serotonin syndrome.
- **Serotonergic drugs, bupropion, tapentadol, tramadol:** Risk of serotonin syndrome
- **TCAs and nabilone**: may increase risk of cardiovascular adverse events.
- **Anticonvulsants (e.g. phenobarbital, phenytoin, primidone)**: Metabolism may be inhibited and absorption may be delayed by dexamfetamine. Dose adjustment may be required when stopping or starting dexamfetamine.
- **Antacids** (e.g. sodium bicarbonate) **and urinary alkalinizing agents** (e.g. acetazolamide, some thiazides): may increase exposure to dexamfetamine
- **Gastrointestinal acidifying agents** (e.g. ascorbic acid, fruit juices) and **urinary acidifying agents** (e.g. ammonium chloride, sodium acid phosphate): may reduce exposure to dexamfetamine
- **Antihistamines:** sedative effect may be counteracted
- **Antihypertensives, including guanethidine**: effects may be reduced by dexamfetamine
- **Beta-blockers (e.g. propranolol)**: risk of severe hypertonia. May reduce effects of dexamfetamine
- **Lithium, phenothiazines, haloperidol**: may reduce the effects of dexamfetamine

- **Disulfiram**: may inhibit metabolism and excretion of dexamfetamine
- **Opioids**: analgesic effects may be increased and the depressant effects (e.g. respiratory depression) may be decreased by dexamfetamine
- **Halogenated anaesthetics:** risk of sudden blood pressure increase during surgery. Avoid dexamfetamine on the day of planned surgery.
- **Cytochrome P450 (CYP450) substrates, inducers or inhibitors**: use with caution; role of CYP450 in dexamfetamine metabolism is not known
- **Alcohol:** may exacerbate adverse CNS effects of dexamfetamine
- **Apraclonidine:** effects decreased by dexamfetamine
- **Ritonavir, tipranavir:** may increase exposure to dexamfetamine

8. Baseline investigations, initial monitoring and ongoing monitoring to be undertaken by specialist

Back to top

Monitoring at baseline and during initiation is the responsibility of the specialist; only once the patient is optimised on the chosen medication with no anticipated further changes expected in immediate future will prescribing and monitoring be transferred to primary care.

Baseline investigations:

- A medical history and cardiovascular assessment, taking into account conditions that may be contraindications, risk of pregnancy (where applicable), and to ensure the patient meets the criteria for ADHD and that pharmacological treatment is required
- A risk assessment for substance misuse and drug diversion
- Blood pressure (BP) and heart rate
- Height, weight and body mass index (BMI)
- Appetite
- Arrange for electrocardiogram (ECG), only if the patient has any of the following:
  - History of congenital heart disease or previous cardiac surgery
  - Sudden death in a first-degree relative under 40 years suggesting a cardiac disease
  - Shortness of breath on exertion compared with peers
  - Fainting on exertion or in response to fright or noise
  - Palpitations
  - Chest pain suggestive of cardiac origin
  - Signs of heart failure, heart murmur or hypertension
  - Current treatment with a medicine that may increase cardiac risk

Initial monitoring:

- After every change of dose: assess heart rate and blood pressure, changes in weight, and any new or worsening psychiatric symptoms. The specialist should determine the appropriate timing for this monitoring.
- Assessment of symptom improvement. Discontinue if no improvement is observed after reaching normal therapeutic doses.

Ongoing monitoring (ADHD):

Ensure the patient receives a review at least annually with a healthcare professional with training and expertise in managing ADHD. This may be in primary or secondary care, depending on local arrangements, and should include a review of ADHD medication, including patient preferences, benefits, adverse effects, and ongoing clinical need. Consider trial periods of stopping medication or reducing the dose when assessment of the overall balance of benefits and harms suggests this may be appropriate. If continuing medication, document the reasons why.

Review outcomes should be communicated to the primary care prescriber in writing, with any urgent changes also communicated by telephone.

In BNSSG the annual review is done in primary care for patients registered at GP practices signed up to the ADHD locally enhanced service (LES) and by the specialist team where the GP practice is not signed up to the LES.

Patients should be encouraged to consider stopping the medication every 1 to 5 years, with the guidance of the specialist clinic if desired. If desired and clinically appropriate, dexamfetamine can be restarted by the GP, referral back into the ADHD service is not necessary.

9. Ongoing monitoring requirements to be undertaken by primary care

Back to top

See section 10 for further guidance on management of adverse effects/responding to monitoring results.

Monitoring	Frequency
• Blood pressure and heart rate • Weight and appetite • Assessment for new or worsening psychiatric and neurological signs or symptoms (e.g. tics, anxiety, symptoms of bipolar disorder). Ask patients “Do you	Every 6 months, and after any change of dose recommended by specialist team.

believe your mental wellbeing has suffered due to your ADHD medications?” • Explore whether patient is experiencing any difficulties with sleep	
• Assessment of adherence, and for any indication of dexamfetamine abuse, misuse, or diversion	As required, based on the patient’s needs and individual circumstances
• Review to ensure patient has been offered and attended an annual review with a healthcare professional with expertise in ADHD	Annually
(If relevant) If monitoring results are forwarded to the specialist team, please include clear clinical information on the reason for sending, to inform action to be taken by secondary care.	

10. Adverse effects and other management

Back to top

Any serious adverse reactions should be reported to the MHRA via the Yellow Card scheme. Visit www.mhra.gov.uk/yellowcard

For information on incidence of ADRs see relevant summaries of product characteristics

Result	Action for primary care
As well as responding to absolute values in laboratory tests, a rapid change or a consistent trend in any value should prompt caution and extra vigilance.	
Resting HR greater than 120bpm, arrhythmia/palpitations, clinically significant increase in systolic BP	• In context of recent dose increase, revert to previous dose and discuss with specialist for ongoing management • In absence of recent dose changes, reduce dose by half and discuss with specialist or cardiology for further advice.
New or worsening seizures	Stop dexamfetamine and discuss with specialist. Discontinuation may be indicated.
Anorexia or weight loss, weight or BMI outside healthy range	Exclude other reasons for weight loss. Exclude other reasons for weight loss. Give advice as per NICE NG87:

	• take medication with or after food, not before • additional meals or snacks early in the morning or late in the evening when stimulant effects have worn off • obtaining dietary advice • consuming high-calorie foods of good nutritional value Discuss with specialist if difficulty persists; dose reduction, treatment break, or change of medication may be required.
Insomnia, sleep disturbance/nightmares, sedation, sexual dysfunction	Review timing of doses and continue treatment unless severe, Give advice on sleep hygiene. Discuss with specialist if required
Nausea, diarrhoea, abdominal cramps, constipation, dry mouth, headache, dizziness, enuresis, increased daytime urination, tics	Continue treatment unless severe. Some symptoms may be alleviated by concomitant food intake. Discuss with specialist if required
New or worsening psychiatric or neuropsychiatric symptoms, e.g. mania, depression, paranoia, anxiety and agitation. NB: psychosis may occur following consumption of very high doses.	Discuss with specialist. Stop treatment and consider referral to acute mental health team if suicidal thoughts, mania, or psychosis are present
Symptoms of serotonin syndrome, e.g. agitation, hallucinations, coma, tachycardia, labile blood pressure, hyperthermia, hyperreflexia, incoordination, rigidity, nausea, vomiting, diarrhoea	Discontinue dexamfetamine as soon as possible. Management depends on severity; use clinical judgement and seek advice if necessary. Discuss with specialist team to determine whether dexamfetamine can be re-started.
Suspicion of abuse, misuse, or diversion	Discuss with specialist team

11. Advice to patients and carers

Back to top

The specialist will counsel the patient with regard to the benefits and risks of treatment and will provide the patient with any relevant information and advice, including patient information leaflets on individual medicines.

The patient/carer should be advised to report any of the following signs or symptoms to their primary care prescriber without delay:

- Any mood changes, such as depression, paranoia, anxiety or agitation, psychosis, mania, and suicidal ideation
- Palpitations, chest pain or syncope
- Cerebrovascular symptoms, such as severe headache, numbness, weakness, paralysis, and impairment of coordination, vision, speech, language, or memory
- Abdominal pain, malaise, jaundice or darkening of urine
- Skin rashes, or bruising easily
- If they suspect they may be pregnant, or are planning a pregnancy. Patients of childbearing potential should use appropriate contraception, and take a pregnancy test if they think there is a possibility they could be pregnant.

The patient/carer should be advised:

- Attend regularly for monitoring and review appointments with primary care and specialist, and keep contact details up to date with both prescribers. It may not be safe to continue prescribing without regular review, and patients should be aware that their medicines could be stopped if they do not attend appointments.
- Dexamfetamine can affect impair cognitive function and is subject to drug driving laws, therefore patients must ensure their ability to drive is not impaired before driving. For information on 2015 legislation regarding driving whilst taking certain controlled drugs, including amfetamines, see drugs and driving: the law. People who drive must inform the DVLA if their ADHD, or medicines affect their ability to drive safely. See https://www.gov.uk/adhd-and-driving
- Avoid alcohol while taking dexamfetamine, as it may make some side effects worse. Avoid recreational drugs. Due to the risks of severe depression, over-activity, extreme fatigue as

well as changes in the EEG during sleep, abrupt withdrawal after a prolonged period of intake of high doses of dexamfetamine should be avoided. Patients wishing to reduce their dose or stop dexamfetamine treatment should discuss with their specialist before doing so.

- Dexamfetamine is a schedule 2 controlled drug. Patients may be required to prove their identity when collecting prescriptions, and should store dexamfetamine safely and securely. It must not be shared with anyone else. There are restrictions on travelling with controlled drugs: see https://www.gov.uk/guidance/controlled-drugs-personal-licences.

Patient information:

- Royal College of Psychiatrists – ADHD in adults. https://www.rcpsych.ac.uk/mental-health/problems-disorders/adhd-in-adults
- NHS – Attention deficit hyperactivity disorder. https://www.nhs.uk/conditions/attention-deficit-hyperactivity-disorder-adhd/

12. Pregnancy, paternal exposure and breast feeding

Back to top

It is the responsibility of the specialist to provide advice on the need for contraception to male and female patients on initiation and at each review, but the ongoing responsibility for providing this advice rests with both the primary care prescriber and the specialist.

Pregnancy:

Dexamfetamine is not recommended for use during pregnancy The limited data available shows a risk of premature birth and reduced birth weight. Infants may also develop withdrawal symptoms such as dysphoria, hyperexcitability and pronounced exhaustion.

If a patient becomes pregnant or is planning a pregnancy during treatment they should discuss treatment options with their specialist. Ongoing prescribing in pregnancy may be managed in primary care within the competence of the prescriber with advice/input from the specialist.

Healthcare professional information available from: https://www.medicinesinpregnancy.org/bumps/monographs/USE-OF-AMFETAMINES-IN-PREGNANCY/

Breastfeeding:

Dexamfetamine is excreted in human milk, therefore a risk to infants cannot be excluded. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from

dexamfetamine, taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman. High doses may interfere with lactation, although this is not confirmed in practice. If breastfeeding does take place, infants should be monitored for symptoms of CNS stimulation (e.g. decreased appetite/weight gain, sleep disturbances, irritability), although these may be difficult to detect.

Healthcare professional information available from: Breastfeeding Medicines Advice service – SPS - Specialist Pharmacy Service – The first stop for professional medicines advice

Paternal exposure:

No evidence regarding adverse outcomes following paternal exposure was identified. Further information for patients: https://www.medicinesinpregnancy.org/leaflets-a-z/dexamfetamine/

13. Specialist contact information

Back to top

Name: *Dr Dietmar Hank*

Role and specialty: Consultant Psychiatrist and Clinical Lead Adult ADHD service, AWP

Daytime telephone number: 01275 796262 M-F 9-5

Email address: *Awp.specialisedadhdservices@nhs.net*

Alternative contact: *[insert contact information, e.g. for clinic or specialist nurse]*

Out of hours contact details: *[insert contact information, e.g. for duty doctor]*

14. Additional information

Back to top

Where patient care is transferred from one specialist service or GP practice to another, a new shared care agreement must be completed. Ensure that the specialist is informed in writing of any changes to the patient's GP or their contact details.

15. References

Back to top

- NICE NG87: Attention deficit hyperactivity disorder: diagnosis and management. Last updated September 2019. Accessed via https://www.nice.org.uk/guidance/ng87/ on 16/01/2025
- eBNF. Dexamfetamine. Accessed via https://bnf.nice.org.uk/ on 16/01/2025
- Dexamfetamine sulfate 20 mg tablets (Amfexa®). Accessed via https://www.medicines.org.uk/emc/product/7404/smpc on 16/01/2025
- Dexamfetamine sulfate 5mg tablets (Amfexa®). Accessed via https://www.medicines.org.uk on 16/01/2025
- Dexamfetamine sulfate Prescribing Support (risk minimisation materials). Accessed via https://www.medicines.org.uk/emc/rmm-directory/?searchfieldrisk=dexamfetamine#gref on 16/01/2025
- NICE. NG46: Controlled drugs: safe use and management. April 2016. Accessed via https://www.nice.org.uk/guidance/ng46/ on 16/01/2025
- NICE Clinical Knowledge Summaries. Attention deficit hyperactivity disorder: Amfetamines. Last revised December 2024. Accessed via https://cks.nice.org.uk/topics/attention-deficit-hyperactivity-disorder/prescribing-information/amfetamines/ on 16/01/2025
- Gov.uk. Drugs and driving: the law. Accessed via https://www.gov.uk/drug-driving-law on 16/01/2025

16. Other relevant national guidance

Back to top

- NHSE guidance – Responsibility for prescribing between primary & secondary/tertiary care. Available from https://www.england.nhs.uk/publication/responsibility-for-prescribing-between-primary-and-secondary-tertiary-care/
- General Medical Council. Good practice in prescribing and managing medicines and devices. Shared care. Available from https://www.gmc-uk.org/ethical-guidance/ethical-guidance-for-doctors/good-practice-in-prescribing-and-managing-medicines-and-devices/shared-care
- NICE NG197: Shared decision making. Last updated June 2021. https://www.nice.org.uk/guidance/ng197/.

17. Local arrangements for referral

Back to top

Define the referral procedure from hospital to primary care prescriber & route of return should the patient's condition change.

Contact specialist for advice if:

- The patient finds the medication intolerable for any given reason
- If there is concern about observed mental or physical side effects (e.g. depression or hypertension)
- The side effects mentioned above, do not appear to be of a temporary and short lived nature Contact named responsible clinician in writing or via secure email detailed in clinic

Contact named responsible clinician in writing or via secure email detailed in clinic letter. See flow diagram below for referral pathways for GP practices signed up to the ADHD LES.

Approved by BNSSG JFG: January 2025
Review date: September 2027
Version 1

BNSSG Adult ADHD referral and treatment pathway – GP Practices signed up to ADHD LES



BNSSG Adult ADHD referral and treatment pathway – GP Practices signed up to ADHD LES